MGMT and glioblastoma: Moreover, the Phase 1 clinical trial (NCT04842513) is recruiting participants for an immunomodulating multi-peptide vaccine using Pam3Cys-GDPKHPKSF (XS15) for patients with newly diagnosed MGMT-methylated glioblastoma who are HLA-A2-positive.